Category Archives: Cancer and neoplasms

Sheela Abraham Queen’s Health Sciences researchers are part of a multi-institutional research team that will receive $2.4 million to advance cancer research and treatment. The collaborative team – led by principal investigators at Sunnybrook Research Institute and Princess Margaret Cancer Centre – is behind one of five projects to receive funding in the 2023 Terry […]

Breelyn Wilky, MD The activity generated by the combination of doxorubicin, zalifrelimab (AGEN1884), and balstilimab (AGEN2034) in patients with advanced/metastatic soft tissue sarcoma indicated a potential pathway for the use of immunotherapy in this patient population, which has historically been associated with immunologically cold tumors, according to Breelyn Wilky, MD. Data from a single-arm, open-label […]

John A. Carucci, MD, PhD Credit: NYU Langone Health In cases of initial Merkel cell carcinoma (MCC) where regional lymph node disease is pathologically determined to be negative, new findings suggest Mohs micrographic surgery instead of wide local excision could lead to greater rates of patient survival.1 The study which led to these findings assessed […]

Study design and participants We performed a retrospective cohort analysis using data from the National Health and Nutrition Examination Survey (NHANES), a representative sample of non-institutionalized US residents linked with the National Center for Health Statistics (NCHS) 2019 National Death Index (NDI) file. The NHANES program oversamples those aged 60 and older, Latinx and non-Hispanic […]

Abstract The myeloid neoplasms encompass acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data from 454,340 UK Biobank participants, of whom 1,808 developed a myeloid neoplasm 0–15 years after recruitment. We describe the differences in CH mutational landscapes and hematology/biochemistry test parameters […]

Osteoarthritis, the most common form of arthritis, currently affects 14.8% of the global population over the age of 30. The number of cases is predicted reach 1 billion by the year 2050, with aging, population growth, and obesity cited as key factors, according to a study published in The Lancet.1 Jaimie Steinmetz, PhD Credit: TheConversation.com […]

Meletios A. Dimopoulos, MD Patients with symptomatic Waldenström macroglobulinemia (WM) achieved superior responses with Zanubrutinib (Brukinsa) compared with ibrutinib (Imbruvica), according to a final analysis of the phase 3 ASPEN study (NCT03053440), which was published in the Journal of Clinical Oncology. At a median follow-up of 44.4 months (range, 0.4-57.3), patients in cohort 1 with MYD88-mutated WM […]